Bicycle Therapeutics (BCYC)

• Market cap: $991M
• 1 day: -2.25%
• 5 days: -4.33%
• 1 month: -28.07%
• 3 months: -40.13%
• 6 months: -30.17%
• Year to date: -22.18%
• 1 year: -22.89%
• 5 years: 78.93%
• 10 years: 19.58%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Employees: 284

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

40% more call options, than puts

Call options by funds: $793K | Put options by funds: $567K

10% more capital invested

Capital invested by funds: $829M [Q2] → $915M (+$86.4M) [Q3]

3% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 33

0% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]

1% less funds holding

Funds holding: 106 [Q2] → 105 (-1) [Q3]

5% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 19

5.87% less ownership

Funds ownership: 91.01% [Q2] → 85.14% (-5.87%) [Q3]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $17 18% upside
• Avg. target: $29 102% upside
• High target: $38 165% upside

6 analyst ratings

• positive: 4 67%
• neutral: 2 33%
• negative: 0 0%

JMP Securities Reni Benjamin 17% 1-year accuracy 6 / 36 met price target	81% upside $26	Market Outperform Maintained	18 Dec 2024
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 52 / 173 met price target	130% upside $33	Buy Maintained	16 Dec 2024
B. Riley Securities Kalpit Patel 33% 1-year accuracy 3 / 9 met price target	18% upside $17	Neutral Maintained	13 Dec 2024
Stephens & Co. Sudan Loganathan 26% 1-year accuracy 5 / 19 met price target	74% upside $25	Equal-Weight Initiated	8 Nov 2024
RBC Capital Gregory Renza 40% 1-year accuracy 32 / 81 met price target	144% upside $35	Outperform Reiterated	1 Nov 2024